查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
孕產婦心理健康市場--全球產業分析、規模、份額、成長、趨勢、區域前景、預測（2023-2030）-（按適應症、治療方法、地區、公司）
市場調查報告書
商品編碼
1358262

孕產婦心理健康市場--全球產業分析、規模、份額、成長、趨勢、區域前景、預測（2023-2030）-（按適應症、治療方法、地區、公司）

Maternal Mental Health Market - Global Maternal Mental Health Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Disease Indication Coverage, By Therapy Coverage, By Geographic Coverage and By Company)
出版日期: | 出版商: Fairfield Market Research | 英文 270 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

到 2030 年底，全球孕產婦心理健康市場規模預計將達到 400 億美元的重要估值，2023 年至 2030 年複合年增長率穩定達到 28%。 這一前所未有的增長是由政府增加旨在降低孕產婦死亡率的資金、產後抑鬱症發病率急劇上升、擴大認識計劃以及不斷努力加強與孕產婦心理健康相關的做法推動的。

孕產婦心理健康市場的快速擴張是由積極的報銷情況、產後憂鬱症 (PPD) 患病率上升、廣泛宣傳舉措的實施以及強大可靠的醫療基礎設施等因素推動的。由極其重要的因素組合支持。

產後憂鬱症是一種對產婦產後心理健康影響重大的疾病，由於其發生廣泛、影響嚴重，在孕產婦心理健康領域佔有最大的市場份額。

人際關係治療 (IPT) 以其在解決基於關係的壓力源和增強圍產期產婦福祉方面的有效性而聞名，已成為孕產婦心理健康市場的領先治療方法。

受益於專業護理、諮詢服務和支持團體的增加，北美繼續處於孕產婦心理健康市場的前沿。 該地區先進的醫療基礎設施和積極主動的孕產婦心理健康方法奠定了其領先地位。

亞太地區已成為成長最快的市場，人們對孕產婦心理健康問題的認識不斷提高。 該地區的經濟成長改善了醫療保健基礎設施、改善了醫療設施的使用以及對婦女健康的關注。

本報告調查了全球孕產婦心理健康市場，並提供了市場概況、按疾病適應症、治療方法、地區劃分的趨勢以及進入市場的公司的競爭趨勢。

目錄

第 1 章執行摘要

第 2 章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • PESTLE分析

第 3 章 2018-2030 年全球孕產婦心理健康市場展望

  • 2018-2030 年全球孕產婦心理健康市場前景按適應症劃分、金額（十億美元）
  • 2018-2030 年全球孕產婦心理健康市場前景按治療方法、金額（十億美元）
  • 2018-2030 年全球孕產婦心理健康市場展望按地區、金額（十億美元）

第 4 章 2018-2030 年北美孕產婦心理健康市場前景

第 5 章歐洲孕產婦心理健康市場展望，2018-2030

第 6 章亞太地區孕產婦心理健康市場展望，2018-2030

第 7 章拉丁美洲孕產婦心理健康市場展望，2018-2030

第 8 章中東與非洲孕產婦心理健康市場前景，2018-2030

第 9 章競爭態勢

  • 疾病適應症與用途熱圖
  • 製造商和應用程式的熱圖
  • 2022 年公司市佔率分析
  • 競爭力儀表板
  • 公司簡介
    • Pfizer, Inc.
    • Lipocine, Inc.
    • Viatris Inc.
    • GlaxoSmithKline plc
    • Alembic Pharmaceuticals Limited
    • Mallinckrodt, Inc.
    • Sage Therapeutics, Inc.
    • Bold Health
    • Bausch Health Companies Inc.
    • Magellan Health, Inc.

第 10 章附錄

簡介目錄

Global Maternal Mental Health Market Poised for Remarkable Growth, Projected to Reach US$40 Billion by 2030.

The global maternal mental health market is on track to achieve a substantial valuation of US$40 billion by the close of 2030, driven by a robust compound annual growth rate (CAGR) of 28% during the period from 2023 to 2030. This unprecedented growth is attributed to several key factors, including increased government funding aimed at reducing maternal mortality, a surge in the incidence of postpartum depression, expanding awareness programs, and ongoing efforts to enhance practices related to maternal mental health.

Market Insights in Brief

The maternal mental health market's rapid expansion is underpinned by a combination of pivotal drivers, including positive reimbursement scenarios, a rising prevalence of postpartum depression (PPD), the implementation of widespread awareness initiatives, and the presence of a robust and reliable healthcare infrastructure.

Postpartum depression, a condition with significant implications for the mental well-being of postpartum mothers, commands the largest market share in the maternal mental health sector due to its widespread occurrence and profound impact.

Interpersonal therapy (IPT) has emerged as a leading therapeutic approach in the maternal mental health market, known for its effectiveness in addressing relationship-based stressors and enhancing maternal well-being during the perinatal period.

Regional Dynamics

North America remains at the forefront of the maternal mental health market, benefiting from enhanced accessibility to specialized care, counseling services, and support groups. The region's advanced healthcare infrastructure and proactive approach towards maternal mental health have contributed to its leadership position.

Asia Pacific, experiencing a surge in awareness about maternal mental health issues, is emerging as the fastest-growing market. The region's economic growth has led to improved healthcare infrastructure, increased access to medical facilities, and a growing emphasis on women's health.

Growth Drivers

  • 1. Growing Government Funds Targeting Reduced Maternal Mortality

Government investments in mental health services and support for pregnant and postpartum women have played a pivotal role in reducing the risk of maternal mental health disorders. These funds have led to the expansion of maternal mental health services, including early detection, counseling, specialized clinics, and awareness campaigns, thereby reducing stigma and encouraging more women to seek help during pregnancy and postpartum periods.

  • 2. Growing Incidences of Postpartum Depression

The rising prevalence of postpartum depression, coupled with improved screening and detection measures, has resulted in a higher demand for maternal mental health services. Timely intervention for postpartum depression is recognized as crucial to prevent long-term impacts on both mother and child well-being, further driving market growth.

Challenges

Mental Health Workforce Shortage

Despite the growing demand for mental health services during the perinatal period, a shortage of qualified experts remains a significant constraint. This scarcity leads to long wait times for appointments, limited access to specialized treatment, and delayed interventions, potentially affecting the health outcomes of pregnant and postpartum women.

Competitive Landscape

Key players in the maternal mental health market include: Lipocine, Inc., Pfizer, Inc., Viatris, Inc., Bold Health, GlaxoSmithKline Inc., Alembic Pharmaceuticals Limited, Mallinckrodt, Inc., Sage Therapeutics, Inc., Bausch Health Companies Inc., and Magellan Health, Inc.

The global maternal mental health market's remarkable growth trajectory underscores its pivotal role in safeguarding the well-being of mothers and the health and development of their children. As governments, healthcare providers, and the private sector continue to invest in this critical healthcare segment, the market is poised to make substantial strides in the years ahead.

Table of Contents

1. Executive Summary

  • 1.1. Global Maternal Mental Health Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Maternal Mental Health Market Outlook, 2018 - 2030

  • 3.1. Global Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Postpartum Depression
      • 3.1.1.2. Dysthymia
      • 3.1.1.3. Pregnancy and Postpartum General Anxiety
      • 3.1.1.4. Pregnancy and Postpartum OCD
      • 3.1.1.5. Birth-Related PTSD
      • 3.1.1.6. Others
  • 3.2. Global Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Antidepressants
        • 3.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 3.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 3.2.1.1.3. Other
      • 3.2.1.2. Interpersonal Psychotherapy (IPT)
      • 3.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 3.2.1.4. Other
  • 3.3. Global Maternal Mental Health Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Maternal Mental Health Market Outlook, 2018 - 2030

  • 4.1. North America Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Postpartum Depression
      • 4.1.1.2. Dysthymia
      • 4.1.1.3. Pregnancy and Postpartum General Anxiety
      • 4.1.1.4. Pregnancy and Postpartum OCD
      • 4.1.1.5. Birth-Related PTSD
      • 4.1.1.6. Others
  • 4.2. North America Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Antidepressants
        • 4.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 4.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 4.2.1.1.3. Other
      • 4.2.1.2. Interpersonal Psychotherapy (IPT)
      • 4.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 4.2.1.4. Other
    • 4.2.2. Market Attractiveness Analysis
  • 4.3. North America Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 4.3.1.2. U.S. Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 4.3.1.3. Canada Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 4.3.1.4. Canada Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Maternal Mental Health Market Outlook, 2018 - 2030

  • 5.1. Europe Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Postpartum Depression
      • 5.1.1.2. Dysthymia
      • 5.1.1.3. Pregnancy and Postpartum General Anxiety
      • 5.1.1.4. Pregnancy and Postpartum OCD
      • 5.1.1.5. Birth-Related PTSD
      • 5.1.1.6. Others
  • 5.2. Europe Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Antidepressants
        • 5.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 5.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 5.2.1.1.3. Other
      • 5.2.1.2. Interpersonal Psychotherapy (IPT)
      • 5.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 5.2.1.4. Other
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.2. Germany Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.3. U.K. Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.4. U.K. Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.5. France Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.6. France Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.7. Italy Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.8. Italy Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.9. Turkey Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.10. Turkey Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.11. Russia Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.12. Russia Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.13. Rest Of Europe Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.14. Rest Of Europe Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Maternal Mental Health Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Postpartum Depression
      • 6.1.1.2. Dysthymia
      • 6.1.1.3. Pregnancy and Postpartum General Anxiety
      • 6.1.1.4. Pregnancy and Postpartum OCD
      • 6.1.1.5. Birth-Related PTSD
      • 6.1.1.6. Others
  • 6.2. Asia Pacific Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Antidepressants
        • 6.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 6.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 6.2.1.1.3. Other
      • 6.2.1.2. Interpersonal Psychotherapy (IPT)
      • 6.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 6.2.1.4. Other
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.2. China Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.3. Japan Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.4. Japan Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.5. South Korea Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.6. South Korea Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.7. India Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.8. India Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.9. Southeast Asia Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.10. Southeast Asia Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.11. Rest of Asia Pacific Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.12. Rest of Asia Pacific Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Maternal Mental Health Market Outlook, 2018 - 2030

  • 7.1. Latin America Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Postpartum Depression
      • 7.1.1.2. Dysthymia
      • 7.1.1.3. Pregnancy and Postpartum General Anxiety
      • 7.1.1.4. Pregnancy and Postpartum OCD
      • 7.1.1.5. Birth-Related PTSD
      • 7.1.1.6. Others
  • 7.2. Latin America Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Antidepressants
        • 7.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 7.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 7.2.1.1.3. Other
      • 7.2.1.2. Interpersonal Psychotherapy (IPT)
      • 7.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 7.2.1.4. Other
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.2. Brazil Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 7.3.1.3. Mexico Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.4. Mexico Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 7.3.1.5. Argentina Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.6. Argentina Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 7.3.1.7. Rest of Latin America Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.8. Rest of Latin America Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Maternal Mental Health Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Postpartum Depression
      • 8.1.1.2. Dysthymia
      • 8.1.1.3. Pregnancy and Postpartum General Anxiety
      • 8.1.1.4. Pregnancy and Postpartum OCD
      • 8.1.1.5. Birth-Related PTSD
      • 8.1.1.6. Others
  • 8.2. Middle East & Africa Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Antidepressants
        • 8.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 8.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 8.2.1.1.3. Other
      • 8.2.1.2. Interpersonal Psychotherapy (IPT)
      • 8.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 8.2.1.4. Other
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.2. GCC Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.3. South Africa Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.4. South Africa Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.5. Egypt Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.6. Egypt Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.7. Nigeria Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.8. Nigeria Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.9. Rest of Middle East & Africa Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.10. Rest of Middle East & Africa Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Disease Indication vs Application Heatmap
  • 9.2. Manufacturer vs Application Heatmap
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Lipocine, Inc.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Viatris Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. GlaxoSmithKline plc
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Alembic Pharmaceuticals Limited
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Mallinckrodt, Inc.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Sage Therapeutics, Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Bold Health
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Bausch Health Companies Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Magellan Health, Inc.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations